Vote Scores
Filings read through

Tarsus Pharmaceuticals, Inc.: how funds voted at the meeting of 12 Jun 2025

Ticker
TARS
Meeting
Season
year to 30 June 2025
Filers reporting
311
Ballot items
4

311 filers on Form N-PX reported votes at the Tarsus Pharmaceuticals, Inc. meeting of 12 Jun 2025. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2025. The latest season on file is the year to 30 June 2026. The page of Tarsus Pharmaceuticals, Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2025. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    2 nominees. 80.4% of the reported votes are for. 47 filers withheld from or voted against at least one nominee.

    392 vote records from 115 filers. 1 of the 114 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 39 fund families
    • For 24
    • Split or no vote 15
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    435 vote records from 309 filers. 28 of the 298 filers that marked the item voted against management. 11 filers gave no management mark.

    • Positions of 46 fund families
    • For 46
  3. Item 3: Frequency of the say-on-pay vote

    One year: 284 filers. For: 5 filers. Three years: 4 filers. 1-year: 1 filer. None: 1 filer. Abstain: 1 filer.

    433 vote records from 306 filers. 5 of the 294 filers that marked the item voted against management. 12 filers gave no management mark.

    • Positions of 46 fund families
    • Split or no vote 46
    • Against management 1
  4. Item 4: Audit-related items (auditor ratification)

    196 vote records from 115 filers. 1 of the 114 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 39 fund families
    • For 39

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Tarsus Pharmaceuticals, Inc., meeting of 12 Jun 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Pay-vote frequency4. Auditor
AllianceBernsteinForSplitNo report
AllspringForSplitFor
Artisan PartnersForSplitFor
BairdForSplitFor
BlackRock and iSharesForSplitFor
BNY MellonForSplitNo report
Brighthouse FundsForSplitFor
Charles SchwabForSplitFor
Columbia ThreadneedleForSplitFor
DimensionalForSplit, against managementFor
DWSForSplitFor
EquitableForSplitFor
Federated HermesForSplitFor
FidelityForSplitFor
First TrustForSplitFor
Franklin TempletonForSplitFor
Global XForSplitFor
Goldman SachsForSplitFor
Guggenheim and RydexForSplitFor
Harbor FundsForSplitFor
InvescoForSplitFor
J.P. MorganForSplitNo report
Jackson National fundsForSplitFor
Janus HendersonForSplitNo report
John Hancock and ManulifeForSplitFor
Lincoln FinancialForSplitFor
Lord AbbettForSplitFor
Macquarie and Delaware FundsForSplitFor
MassMutualForSplitNo report
Morgan Stanley, Eaton Vance and CalvertForSplitFor
NationwideForSplitFor
Natixis and Loomis SaylesForSplitNo report
Neuberger BermanForSplitNo report
Northern Trust and FlexSharesForSplitFor
Nuveen and TIAAForSplitFor
Pacific Life fundsForSplitFor
PGIM and PrudentialForSplitFor
PrincipalForSplitFor
ProShares and ProFundsForSplitFor
Russell InvestmentsForSplitFor
SEIForSplitFor
State Street and SPDRForSplitFor
T. Rowe PriceForSplitFor
VanguardForSplitFor
Victory CapitalForSplitFor
VoyaForSplitFor

Questions

How many filers reported votes at the Tarsus Pharmaceuticals, Inc. meeting?
311 Form N-PX filers reported votes at the meeting of 12 Jun 2025. On say-on-pay, 28 of 298 filers that marked the item voted against management (9.4%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Tarsus Pharmaceuticals, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Tarsus Pharmaceuticals, Inc. with a meeting date within three days of 12 Jun 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .